Search alternatives:
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
-
8501
-
8502
-
8503
Synthesis and Fluorescent Properties of a New Class of Heterocycles of Isoindole Fused Imidazoles with Phenolic Subunits
Published 2006“…A new class of heterocycles of isoindole fused imidazoles with phenolic subunits has been readily synthesized by a two-step one-pot reaction. In aprotic solvent they show high fluorescent properties (Φ<sub>F</sub> up to 0.93), but in protic polar solvent fluorescent intensity decreases. …”
-
8504
-
8505
Crystal Structure of YbCu<sub>6</sub>In<sub>6</sub> and Mixed Valence Behavior of Yb in YbCu<sub>6–<i>x</i></sub>In<sub>6+<i>x</i></sub> (<i>x</i> = 0, 1, and 2) Solid Solution
Published 2016“…A deviation in inverse susceptibility data at 200 K suggests a valence transition from Yb<sup>2+</sup> to Yb<sup>3+</sup> as the temperature decreases. …”
-
8506
-
8507
-
8508
-
8509
-
8510
-
8511
-
8512
-
8513
-
8514
Image_3_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif
Published 2022“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
-
8515
Image_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif
Published 2022“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
-
8516
Image_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif
Published 2022“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
-
8517
Table_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx
Published 2022“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
-
8518
Table_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx
Published 2022“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
-
8519
-
8520